

10,520,616

JCOG Rec'd PCT/PTO 14 OCT 2005

DOCKET NO. PRD2023USPCT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : LINDERS, J. T. M. et al.

Serial No. : Not Assigned

Art Unit: Not Assigned

Filed : Herewith

Examiner: Not Assigned

For : Adamantyl Acetamides As 11-Beta Hydroxysteroid
Dehydrogenase Inhibitors

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 12, 2005

(Date of Deposit)

Matthew B. Zisk, Reg. No. 45,257

(Name of applicant, assignee, or Registered Representative)

/Matthew B. Zisk/

(Signature)

October 11, 2005

(Date of Signature)

Commissioner for Patents
Alexandria, VA. 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37
C.F.R. §§1.97-1.98, information relating to the above-identified
application is hereby disclosed. Inclusion of information in
this statement is not to be construed as an admission that this
information is material as that term is defined in 37 C.F.R.
§1.56(b).

Applicant(s) reserve(s) the right to establish the
patentability of the claimed invention over any of the
information provided herewith, and/or to prove that this
information may not be prior art, and/or to prove that this
information may not be enabling for the teachings purportedly
offered.

BEST AVAILABLE COPY

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☐ There are no listed references which are not in the English language.

☒ The relevance of those listed references which are not in the English language is as follows: See attached Abstracts.

☒ Attached is a copy of a search report(s) from a corresponding patent application(s), which is listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/PRD2023USPCT/MBZ. This form is submitted in triplicate.

Respectfully submitted,

/Matthew B. Zisk/

Matthew B. Zisk,
Reg. No. 45,257
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1287
DATED: October 11, 2005

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ . In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	Not yet Assigned
Filing Date	Herewith
First Named Inventor	Joannes T. M. Linders
Group Art Unit	Not yet Assigned
Examiner Name	Not yet Assigned
Attorney Docket Number	PRD 2023USPCT

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
		2,510,945		United States of America	06-13-1950	
		3,526, 656		Parke, Davis & Co.	09-01-1970-	
		3,622,567		Arthur D. Little Inc.	11-23-1971	
		3,919,313		Schering Corporation	11-11-1975	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵				
		FR	1399615	A	Chemical Investors S.A.	05-21-1965		✓
		DE	1959898		J.R. Geigy, A.G.	06-18-1970		✓
		DE	2624290	A	Chinoin Gyogyszer ES Vegyeszet	04-14-1977		✓
		WO	98/11073	A1	Pharmacia & Upjohn Co.	03-19-1998		
		WO	99/26927	A2	NPS Pharmaceutical, Inc.	06-03-1999		
		WO	01/90090	A1	Biovitrum AB	11-29-2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published, city and/or country where published	T ²
		MARKOWNIKOW "Beilstein Institut zur Foerderung der Chemischen Wissenschaften, Frankfurt am Main, DE". <u>Chem. Ber.</u> , 1892, vol. 25, p. 3357, XP-002248050.	Abstract only
		YOUNG, C., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften, Frankfurt am Main, DE". <u>J. Chem. Soc.</u> , 1898, vol. 73, p. 365, XP-002248041	Abstract only
		CAMPS: Beilstein Institut zur Foerderung der Chemischen Wissenschaften, Frankfurt am Main, DE". <u>Arch. Pharm.</u> ; 1902, vol. 240; p. 358; XP002248047.	Abstract only
		FORSTER, A., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Chem. Soc.</u> , 1904, vol. 85, p. 1190, XP-002248034.	✓
		KOETZ, M., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Prakt. Chem.</u> ; 1926, vol. 113, p. 74, XP-002248036.	Abstract only
		GRYSZKIEWICZ-T., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Rocz. Chem.</u> , 1934; vol. 14; p. 335-7; XP002248048.	Abstract only
		SUGASAWA, O. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". 1952, vol. 72, p. 7461, XP002248038.	✓
		GIULIANO, L., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Farmaco</u> , 1952, vol. 7, p. 29-32, XP002248051.	Abstract only
		KNUNJANZ, G. "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>IASKA6</u> , 1958, p. 1219-21, XP002248040.	✓
		TAKAHASHI, T., "Synthesis of analgesics. XX. Camphane derivatives. 2"retrieved from STN". <u>Chem. Abst.</u> 1959, vol. 79, p. 162-6, vol. 79, XP002248033.	Abstract only
		KOENIG, H. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Chem. Ber.</u> , 1965, vol. 98, p. 3712-23, XP002248046.	Abstract only
		JONES, et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Tetrahedron</u> , 1965, vol. 21, p. 2961-66, XP002279296.	Abstract only
		CAGLIOTI, L., et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Org. Chem.</u> , 1968, vol. 33; p. 2979-81, no. 7., XP002248043.	Abstract only
		BONNEKESSEL, J., et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Chem. Ber.</u> 1973, vol. 106, p. 2890-2903, XP002248049.	Abstract only
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	Not yet Assigned
Filing Date	Herewith
First Named Inventor	Joannes T. M. Linders
Group Art Unit	Not yet Assigned
Examiner Name	Not yet Assigned
Attorney Docket Number	PRD 2023USPCT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MIZUNO, K., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Chem. Soc. Chem. Commun.</u> , 1975, p. 308. XP002248042	✓
		OLSEN, C. E., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Acta Chem. Scand. Ser. B.</u> , 1975, p. 953-62, XP002248044	✓
		KUEHNE, M. E., et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Org. Chem.</u> , 1977, vol. 42, p. 2082-87, no. 12, XP002248045	Abstract only
		OLAH, G. A., et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Synthesis</u> , 1979, p. 274-76, XP002248039	✓
		SCHROTH, W. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Prakt. Chem.</u> , 1983, vol. 325, p. 787-802, no. 5, XP002248035	Abstract only
		SABRI, S. S. et al., "Synthesis and antibacterial activity of some new N-(3-methyl-2- quinoxaloyl) amino alcohols and amine 1,4-dioxides". <u>J. Chem. Eng. Data</u> , 1984, p. 229-31, vol. 29, no. 2, XP002279298	Abstract only
		YAMATO, M. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Chem. Pharm. Bull.</u> , 1988, vol. 36, p. 3453-61, no. 9, XP002279297	Abstract only
		ZHOU, L. et al., "Glucocorticoid effects on extracellular matrix proteins and integrins in bovine trabecular meshwork cells in relation to glaucoma". <u>J. J. Mole. Med.</u> , 1998, vol. 339, p. 341-6.	✓
		KITAGAWA, O. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Tetrahedron Lett.</u> , 1999, vol. 40, p. 8827-8832, no. 50, XP002279294	Abstract only
		MONTAGUE, C.T. et al., "Perspectives in Diabetes The Perils of Portliness Causes and Consequences of Visceral Adiposity". <u>Diabetes</u> , 2000, vol. 49, p. 883-888.	✓
		LATYPOV, S. et al., "Determination of the absolute stereochemistry of alcohols and amines by NMR of the group directly linked to the chiral derivatizing reagent". <u>Tetrahedron</u> , 2001, vol. 57, p. 2231-2236, no. 11, XP004230761	✓
		STARNES, S. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>J. Amer. Chem. Soc.</u> , 2001, vol. 123, p. 4659-69, no. 20, XP002248037	Abstract only
		MASUZAKI, H. et al., "A Transgenic Model of Visceral Obesity and the Metabolic Syndrome". <u>Science</u> , 2001, vol. 294, p. 2166-2170.	✓
		RAUZ, S. et al., "Expression and Putative Role of 11 β -Hydrosteroid Dehydrogenase Isozymes within the Human eye". <u>Invest. Opht. Vis. Sc.</u> , 2001, vol. 42, p. 2037-2042.	✓
		STEWART, P. M., et al., "Cortisol, 11 β -hydroxysteroid dehydrogenase type 1 and central obesity". <u>J. Endoc. Meta.</u> , 2002, vol. 13, p. 94-96, no. 3.	✓
		TERAUCHI, J. et al., "Beilstein Institut zur Foerderung der Chemischen Wissenschaften Frankfurt am Main, DE". <u>Tetrahedron</u> , 2003, vol. 14, p. 587-592, no. 5, XP002279295	Abstract only
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--